Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

22nd Annual bioProcessUK Conference 2025

As in previous years, the event will feature pre-conference drinks, a two-day conference, an evening dinner following the first day, an exhibition, awards, student poster [...]

Go to Top